Skye Bioscience, Inc. SKYE
We take great care to ensure that the data presented and summarized in this overview for Skye Bioscience, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SKYE
Top Purchases
Top Sells
About SKYE
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Insider Transactions at SKYE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 13
2024
|
Andrew J. Schwab |
SELL
Open market or private sale
|
Indirect |
13,837
-0.13%
|
$83,022
$6.06 P/Share
|
|
Sep 13
2024
|
5 Am Partners Vii, LLC |
SELL
Open market or private sale
|
Indirect |
13,837
-0.13%
|
$83,022
$6.06 P/Share
|
|
Sep 11
2024
|
Andrew J. Schwab |
SELL
Open market or private sale
|
Indirect |
252,500
-2.27%
|
$1,515,000
$6.6 P/Share
|
|
Sep 11
2024
|
5 Am Partners Vii, LLC |
SELL
Open market or private sale
|
Indirect |
252,500
-2.27%
|
$1,515,000
$6.6 P/Share
|
|
Aug 26
2024
|
Punit Dhillon Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
15,727
+3.67%
|
-
|
|
Mar 13
2024
|
Andrew J. Schwab |
BUY
Grant, award, or other acquisition
|
Indirect |
450,000
+5.09%
|
$4,500,000
$10.0 P/Share
|
|
Mar 13
2024
|
5 Am Partners Vii, LLC |
BUY
Open market or private purchase
|
Indirect |
450,000
+5.09%
|
$4,500,000
$10.0 P/Share
|
|
Feb 29
2024
|
Paul A. Grayson Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+22.41%
|
-
|
|
Feb 29
2024
|
Tuan Tu Diep Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+19.71%
|
-
|
|
Feb 29
2024
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+10.61%
|
-
|
|
Feb 29
2024
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+20.12%
|
-
|
|
Jan 31
2024
|
Andrew J. Schwab |
BUY
Grant, award, or other acquisition
|
Indirect |
5,206,074
+39.59%
|
$10,412,148
$2.31 P/Share
|
|
Jan 31
2024
|
5 Am Partners Vii, LLC |
BUY
Open market or private purchase
|
Indirect |
5,206,074
+39.59%
|
$10,412,148
$2.31 P/Share
|
|
Nov 06
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
194,270
+39.54%
|
-
|
|
Nov 06
2023
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
128,209
+40.84%
|
-
|
|
Nov 06
2023
|
Paul A. Grayson Director |
BUY
Grant, award, or other acquisition
|
Direct |
173,721
+41.36%
|
-
|
|
Aug 29
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
881,000
+2.08%
|
$0
$0.02 P/Share
|
|
Aug 28
2023
|
Punit Dhillon Chief Executive Officer |
BUY
Small Acquisition
|
Direct |
110,000
+0.27%
|
$0
$0.02 P/Share
|
|
Aug 25
2023
|
Paul A. Grayson Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,132,596
+50.0%
|
-
|
|
Aug 25
2023
|
Kaitlyn Melanie Arsenault Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,382,118
+48.2%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 6.4M shares |
|---|---|
| Other acquisition or disposition | 15.7K shares |
| Open market or private purchase | 5.66M shares |
| Open market or private sale | 533K shares |
|---|